Effect of Two Doses of Coenzyme Q10 on Seminal Fluid and Semen Antioxidant Status
The Effect of Two Doses of Coenzyme Q10 on Seminal Fluid Parameters and Antioxidant Status: A Randomised Controlled Trial
1 other identifier
interventional
65
1 country
1
Brief Summary
The study was conducted to assess the impact of two doses of coenzyme Q10 on seminal fluid parameters and antioxidant status in infertile men.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jun 2018
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 20, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
January 25, 2019
CompletedFirst Submitted
Initial submission to the registry
February 20, 2019
CompletedFirst Posted
Study publicly available on registry
February 22, 2019
CompletedFebruary 22, 2019
February 1, 2019
6 months
February 20, 2019
February 20, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (7)
Semen volume (WHO 2010 guidelines)
Semen volume in ml
3 months
Sperm concentration in semen (WHO 2010 guidelines)
Sperm concentration in million/ml
3 months
Sperm motility in semen (WHO 2010 guidelines)
Sperm motility (%)
3 months
Sperm morphology in semen (WHO 2010 guidelines)
Normal sperm morphology (%)
3 months
Seminal plasma TAC
Seminal plasma total antioxidant capacity in mmol/ml
3 months
Seminal plasma CAT
Seminal plasma catalase in U/ml
3 months
Seminal plasma SOD
Superoxide dismutase in U/ml
3 months
Study Arms (2)
Coenzyme Q10 200
ACTIVE COMPARATORCoenzyme Q10 200mg/day for 3 months
Coenzyme Q10 400
ACTIVE COMPARATORCoenzyme Q10 400mg/day for 3 months
Interventions
Eligibility Criteria
You may qualify if:
- History of infertility of at least 12 months despite regular unprotected intercourse.
- Oligoasthenoteratospermia was diagnosed by semen analysis showing abnormal sperm concentration (\<15 million/ml), progressive motility (\<32%), total motility (\<40%) and morphology (\<30% WHO criteria) as defined by WHO manual for semen analysis 2010
You may not qualify if:
- Azoospermia,
- Varicocele,
- Genital tract infection,
- Cryptorchidism,
- Testicular trauma or scrotal surgery,
- Endocrine disorder,
- Systemic illness,
- Smoking
- The presence of female factor
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Fertility Unit, Babyl
Hillah, 00964, Iraq
Related Publications (3)
Alahmar AT. The effects of oral antioxidants on the semen of men with idiopathic oligoasthenoteratozoospermia. Clin Exp Reprod Med. 2018 Jun;45(2):57-66. doi: 10.5653/cerm.2018.45.2.57. Epub 2018 Jun 29.
PMID: 29984205BACKGROUNDAlshahrani S, Aldossari K, Al-Zahrani J, Gabr AH, Henkel R, Ahmad G. Interpretation of semen analysis using WHO 1999 and WHO 2010 reference values: Abnormal becoming normal. Andrologia. 2018 Mar;50(2). doi: 10.1111/and.12838. Epub 2017 Aug 3.
PMID: 28771785BACKGROUNDNadjarzadeh A, Shidfar F, Amirjannati N, Vafa MR, Motevalian SA, Gohari MR, Nazeri Kakhki SA, Akhondi MM, Sadeghi MR. Effect of Coenzyme Q10 supplementation on antioxidant enzymes activity and oxidative stress of seminal plasma: a double-blind randomised clinical trial. Andrologia. 2014 Mar;46(2):177-83. doi: 10.1111/and.12062. Epub 2013 Jan 7.
PMID: 23289958BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ahmed T Alahmar, MBChB, MSC
University of Sumer, Iraq
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Masking Details
- Open Label
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
February 20, 2019
First Posted
February 22, 2019
Study Start
June 1, 2018
Primary Completion
November 20, 2018
Study Completion
January 25, 2019
Last Updated
February 22, 2019
Record last verified: 2019-02
Data Sharing
- IPD Sharing
- Will not share
Patients data are anonymous and in hold with the principal investigator